Health Care Delivery

Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.

How would the proposed Patient Choice, Affordability, Responsibility, and Empowerment Act affect enrollment, premiums, federal spending, and out-of-pocket costs now that an estimated 20 million Americans have become newly insured?

What we're reading, May 26, 2016: South Carolina passes a 20-week abortion ban, while Georgia's own law faces a new challenge; the FDA delays its decision on a controversial drug for Duchenne muscular dystrophy; and report highlights how Cover Oregon was mishandled.

The smallest overall increase in the MMI in 15 years is masked by the fact that employees are bearing an increasingly large share of healthcare costs.

California’s approach to the healthcare marketplace, Covered California, has successfully held down premium costs because it has authority to select health insurers.

A survey conducted by MaPS/Millward Brown Analytics, on behalf of Memorial Sloan Kettering Cancer Center, has identified multiple concerns of American consumers with cancer clinical trial participation, which could be responsible for the dismal 4% national enrollment rate in clinical trials.